Health Care·Biotechnology·$6.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-2.12 | N/A | -128.69% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-2.12 | N/A | -128.69% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management acknowledged the challenges faced during the quarter. They emphasized their commitment to long-term goals despite current setbacks.
Management did not provide specific guidance for future quarters.
The company is focused on its ongoing strategic initiatives.
Arcellx Inc's earnings report showed a significant loss per share, which contributed to a 3.53% drop in stock price. The lack of revenue information and guidance may leave investors uncertain about the company's short-term prospects. The management's defensive tone suggests they are navigating through challenges while focusing on long-term strategies.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AST SPACEMOBILE INC Class A
Nov 14, 2022